MosaicRx · Patent pending · Pre-pilot

Medication risk, recomputed against the patient in front of you.

MosaicRx is designed to surface the medication risks that matter most for a specific patient, conditioned on that patient's current physiology, and show the reasoning behind every determination.

Built for value-based care teams managing complex older adults.
Encounter · M. Alvarez, 78
Live
Top 3 risks · prioritized
Surfaced at prescribing moment · rank by relevance
Glass Box
  • Elevated anticholinergic burden

    High

    Cumulative ACB score 7 across 3 active meds - associated with cognitive slowing & falls.

  • Prescribing cascade signal

    Watch

    Diuretic started 14 days after NSAID initiation - temporal pattern consistent with cascade.

  • Fall-risk phenotype: high

    High

    Orthostatics + sedating load + recent gait change. Phenotype match 0.89.

Medication timeline
last 90d
Lisinopril
NSAID
Diuretic
Statin
Today

Illustrative example. Not a real patient.

The prescribing cascade

The most expensive medication errors don't look like errors.

They look like new diseases - until a patient falls, becomes delirious, or lands in the ED. By then, the chain is invisible.

01
A medication causes a subtle side effect
02
The side effect is misread as a new condition
03
A new medication is prescribed to treat it
04
Burden compounds - sedation, orthostasis, confusion
05
Fall, delirium, ED visit, readmission

A cascade starts when a medication side effect gets read as a new condition. The new condition gets treated. The patient now carries both drugs, and the second one often carries its own side effect. Nobody made an error at any single step, which is why these are so hard to catch by looking at one prescription at a time.

How it conditions

The same medication list is not the same risk in every patient.

Standard burden scoring treats each drug as carrying a fixed weight. A patient with stage four kidney disease clears those drugs differently, so the identical list carries different risk. MosaicRx is designed to adjust both the burden score and the threshold it is measured against, as functions of the patient's current physiology.

Nominal

  • Anticholinergic burden: 3.0
  • Threshold: 3.0
  • Status: Within range

Conditioned on stage four CKD

  • Anticholinergic burden: 4.2
  • Threshold: 3.0
  • Status: Elevated

Illustrative example. Not a real patient.

Nothing about the prescription changed. The patient did.

A burden of three in stage four kidney disease is not a three.
The product

Top 3 risks · why they matter · what's driving them.

MosaicRx is designed as a prioritized, patient-specific medication-risk review at the prescribing moment, not another alert. Clinical utility will be evaluated in the pilot.

  • Phenotype-specific, not population-generic

    Risks are intended to be scored against the patient's longitudinal trajectory, not a static drug-drug table.

  • Glass Box explainability

    Every signal is designed to expose its evidence trail: contributing meds, timing, and the questions worth reviewing.

  • Clinician-in-the-loop, always

    MosaicRx is designed to surface risks. The clinician decides. Nothing auto-prescribes, nothing auto-stops.

  • It tells you what it ruled out.

    MosaicRx is designed to show when it evaluates a hypothesis and rejects it, with the work: the hypothesis considered, the pharmacologic and temporal reasoning behind the rule-out, and the agents examined and excluded with grounds. A tool that speaks only when it has something to flag gives you no way to know whether it looked.

  • Every response teaches the engine.

    When a clinician responds to a determination, the response is intended to be captured as acted on, rationale documented, not relevant, or not actionable today. The distribution across those four states is how we plan to find where the engine is wrong.

Evidence drawer
Elevated anticholinergic burden
Confidence 0.91
Contributing medications
DiphenhydramineOxybutyninAmitriptyline
Why this matters

Cumulative ACB ≥ 3 in adults >75 is associated with cognitive decline, urinary retention, and falls. Patient's score: 7.

Questions to review
  • →Is amitriptyline still needed for sleep, or can it be tapered?
  • →Substitute oxybutynin with mirabegron?
How it works

Three steps. No new workflow.

01

Context capture

EHR data, longitudinal medication history, labs, and real-world inputs where available - assembled into a patient-specific picture.

02

Risk engine

Phenotype-aware models rank by relevance, not completeness. Built explicitly to avoid alert fatigue.

03

Glass Box output

Top 3 risks with evidence trace, contributing meds, timeline, and questions to review. Clinician decides.

The model never makes the clinical claim.

The intended architecture requires every clinical assertion MosaicRx produces to come from a deterministic rules engine with a complete decision log. The language model renders the explanation in readable form. It cannot generate, alter, or extend a clinical claim.

That separation is designed to make every output reproducible and traceable to a specific rule and a specific source. The pilot will evaluate whether running the same patient twice gives the same answer, with the same reasoning, every time.

Why it's different

Three ways a tool can approach medication risk.

Not an alert. Not a scribe. Not a polypharmacy calculator. MosaicRx is designed as a prioritization layer at the prescribing moment, around clinical judgment.

Static pair checking

Flags known drug-drug interactions from a fixed table, without regard to who the patient is. This is what most EHR alerting does, and it is the reason alert fatigue exists.

Forward prediction

Estimates the likelihood of a future event from a trained model. Useful for triage, opaque under questioning, and bounded by the population the model was trained on.

Reverse-causal and profile-conditioned

Starts from what is already happening to the patient, works backward to the medication that most plausibly explains it, and conditions the entire calculation on current physiology. This is where MosaicRx is designed to sit.

EHR alerts
Pharmacist review tools
MosaicRx
Timing
Late - after order
Between encounters
Prescribing moment
Signal quality
Generic drug-drug
Manual review
Phenotype-specific
Alert fatigue
High
N/A (async)
Engineered against
Auditability
Black box rules
Free-text notes
Glass Box evidence trail
Clinician-in-the-loop
Override-driven
Recommendation memo
Surfaces · clinician decides
Implementation
Deep EHR build
Staffing model
Pilotable; integration later
Who it's for

For the clinician making the call, and the team carrying the risk.

MosaicRx has to earn its place with the clinician and the team carrying risk. These are the needs the pilot is designed to evaluate.

For the clinician

You did not go into medicine to fight your inbox or to second-guess a medication list at the end of a long Friday.

  • It watches so you can decide. When an older patient is on ten or more medications, you already sense one of them might be the problem. Finding which one in a fifteen-minute visit is the hard part. MosaicRx is designed to support that review and surface the few things most worth your attention.
  • It stays in the passenger seat. Nothing auto-prescribes and nothing auto-stops. You see the reasoning, you weigh the questions it raises, and you make the call.
  • It gives you something to point to. Every signal is intended to carry its own evidence, so you can review the reasoning with a worried daughter or document your thinking in the chart.
  • It is designed around the moments that matter most. Supporting safer medication review and more time at home are the goals. Whether MosaicRx contributes to those outcomes remains to be evaluated.

The pilot will evaluate whether this approach supports clinical review without adding noise to your day.

For the value-based care leader

When your group carries risk on older, complex patients, medication-driven harm is one of the largest costs you cannot see coming.

  • It targets medication-related cost of care. Falls, delirium, ED visits, and readmissions can affect medical loss ratio. MosaicRx is designed to surface medication-related risks; effects on clinical outcomes and cost have not been established.
  • It is designed with medication-safety quality measures in mind. MosaicRx is intended to address the risks behind the medication-safety measures your plans are scored on by the Healthcare Effectiveness Data and Information Set (HEDIS): Use of High-Risk Medications in Older Adults, Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults, Polypharmacy: Use of Multiple Central Nervous System-Active Medications in Older Adults, and the Potentially Harmful Drug-Disease Interactions in Older Adults measure that flags sedating medications in patients with a history of falls. These are measures where a lower rate means better performance, and MosaicRx is designed to surface those risks with an evidence trail. Any effect on HEDIS or Stars performance remains to be evaluated.
  • It aims to focus your scarce care-management time. MosaicRx is designed to prioritize relevant medication risks rather than flood pharmacists and care managers with noise. The pilot will evaluate usefulness in practice.
  • It starts with measurable questions. A focused pre-pilot workflow can begin without a deep EHR build. Clinical utility, clinician response, and repeat use are planned evaluation endpoints, not proven results.

Clinical outcomes and financial impact require follow-up beyond the initial pilot.

For specialists managing the whole list

Nephrologists already do this, for the kidney. Renal function governs nearly every drug eventually, which is why nephrology is the specialty most willing to question a prescription written by someone else. MosaicRx is designed to apply that same reasoning across the whole medication list, conditioned on the number you are already watching.

The ripple effect

The family feels it too.

Behind most older patients on a long medication list is a family member tracking the pillbox, noticing the new confusion, and quietly wondering why their mother seems worse. As care moves into the home, that family member has become part of the care team.

In 2024, about 59 million U.S. family caregivers provided an estimated $1.01 trillion in unpaid care, a workforce now larger in value than all Medicaid spending (AARP, Valuing the Invaluable 2026).

  • It aims to turn a silent change into a conversation. When a clinician adjusts a medication, the family usually hears only that something changed. MosaicRx is designed to give the clinician an explainable reason to review and share, so the daughter at the bedside can understand the why.
  • It is designed with families in mind. More time at home and fewer medication-related crises are the intent. These outcomes have not yet been demonstrated for MosaicRx.
  • It aims to lighten an invisible load. The burden of a complication extends to family caregiving, missed work, and worry. The pilot begins the evidence-gathering needed to understand any effect on that burden.

MosaicRx stays a clinical tool used by clinicians. Its potential impact on families remains to be evaluated.

Pilot design

What the pilot measures.

The first deployment is planned as a community clinic pilot with a December readout. Planned endpoints are cascade interception rate, change in conditioned medication burden, the distribution of clinician adjudication across the four response states, repeat use, and clinician time recovered.

Outcome validation, meaning whether intercepted cascades translate into fewer falls and fewer avoidable admissions, requires longitudinal follow-up that this pilot is designed to begin rather than to conclude. We will publish what we find, including the parts that do not work.

For the HEOR and evidence lens

Built to generate the evidence, not only the intervention.

For health economics and outcomes research, the question is whether an intervention produces measurable, defensible value in the real world. MosaicRx is designed to generate that evidence as a byproduct of normal use. The planned evidence pipeline would log surfaced risks, clinician responses, and downstream outcomes to support evaluation of medication burden, cognition, and fall risk in older adults.

  • Anticholinergic and psychoactive burden change. Change in average anticholinergic burden and CNS-active and sedative medication load per patient, the exposures most tied to cognition and falls in older adults.
  • Longitudinal clinical outcomes. Change in medication-related falls, delirium, and cognitive and functional decline, along with the avoidable emergency visits and readmissions those events drive.
  • Phenotype-stratified outcomes. Results stratified by the dimensions that actually govern medication risk in this population: cognitive burden, fall risk, activity and functional status, and psychoactive exposure. Physiologic factors that affect drug handling adjust the underlying score but are not the lens.
  • Modeled cost avoided per 1,000 patients. A conservative total-cost-of-care estimate sized for risk-bearing populations.

The intent is to evaluate MosaicRx as both a point-of-care tool and a source of real-world evidence for value demonstration and budget-impact modeling. No clinical or economic benefit has yet been established.

Pre-pilot planning

Pilot MosaicRx in a community clinic.

Designed for risk-bearing outpatient groups managing complex older adults. Start with a focused workflow - integration may follow evaluation.

What you need to start
  • A clinical champion and 3-10 prescribing clinicians
  • Synthetic or de-identified data for the first phase (no integration required)
  • Defined patient cohort (e.g., 65+ with ≥5 active meds)
  • Optional EHR integration scoped after pilot validation
What we plan to measure
  • Cascade interception rate
  • Clinician adjudication across four response states
  • Repeat use per clinician
  • Time recovered per encounter
  • Explainability engagement rate
About us

The team building MosaicRx.

A clinician-aware, builder-first team backed by senior clinical and commercial advisors across Stanford, community medicine, and value-based care.

Founding team
NG
Nihit Gurram
Founder

Operator-clinician translator. Builds at the intersection of value-based care, medication safety, and prescribing workflow.

AP
Avi Prasad
Co-Founder

Chemistry, B.S. Biotechnology and pharmaceutical expertise. Founder of Prasad Marketing Company.

JM
Justino Mora
Co-Founder & CTO

Engineering leader. Built mission-critical civic tech at scale. Owns architecture, security, and the EHR integration path.

Strategic advisors
Dr. Prashanth Krishnamohan, MD
Stanford Neurology - Line Medical Director Tri-Valley
Clinical signal · neurology workflow
Dr. Andy Le, MD
AZ Medical Clinic
Design partner · community PCP workflow
Dr. Robert Lin, MD, MS
Stanford MCiM
Innovation strategy · clinical translation
Dr. Christina Eldredge, MD, PhD
USF, Clinical Informatics Director
Clinical informatics · academic health systems
Jane Lucero Wulf, RN
CI-Ambulatory, Providence Health
Ambulatory care · nursing operations
Nels Toriano
Summit BP
Business development · GTM
Evans D. Pope III, PharmD
USC, Suncoast Ventures
Pharmacy strategy · venture & commercialization
Priscilla Christie
BD
Partnerships · business development
Daybreak Labs IncubatorNucleate Activator Semifinalist
FAQ

The questions clinical and economic buyers actually ask.

No. MosaicRx is designed as a prioritization layer - it aims to surface the top 3 patient-specific risks ranked by relevance, with the evidence behind each one. It is designed to prioritize relevance and will be evaluated for alert burden: relevance over completeness, signal over noise.
Contact

Request a demo or start a pilot conversation.

Tell us a bit about your team. We'll follow up within two business days.

Clinician-in-the-loop · Glass Box explainability

We use your info only to contact you about MosaicRx.

Prefer email? Reach us directly at nihit@mosaichealthsolutions.io.

Mosaic Health Solutions mosaic cross logo